Bristol Myers Squibb gets EU approval for Sotyktu to treat psoriatic arthritis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
May 8, 2026 6:59 AM EDTIn the pivotal Phase 3 POETYK PsA clinical trials, Sotyktu demonstrated superiority compared with placebo at Week 16 across multiple endpoints, including skin and joint symptoms, with improvements in quality of life as reflected in the European Union Summary of Product Characteristics (SmPC)
Sotyktu, a once-daily oral treatment, is the first and only tyrosine kinase 2 (TYK2) inhibitor to be approved in the European Union for this indication
PRINCETON, N.J.--(BUSINESS... More
